Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | CHUK | O15111 | 2/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.37 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.36 |
| ▸ | AKT1 | P31749 | 4/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | STK4 | Q13043 | 1/20 | 0.32 |
| ▸ | STK3 | Q13188 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.31 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5527750 | 0.83 | RET (0.38) | CHEK1CHUKMAP3K7TAB1HSP90AB1 | |
| SCHEMBL31022852 | 0.78 | CHUK (0.44) | CHUK | |
| SCHEMBL311539 | 0.78 | CHEK1 (0.46) | CHEK1CHUKMAP3K7TAB1HSP90AB1 | |
| SCHEMBL310980 | 0.77 | CHEK1 (0.43) | CHEK1CHUKMAP3K7TAB1HSP90AB1 | |
| SCHEMBL312134 | 0.77 | CHEK1 (0.43) | CHEK1CHUKMAP3K7TAB1HSP90AB1 | |
| SCHEMBL312426 | 0.77 | CHEK1 (0.49) | CHEK1CHUKMAP3K7TAB1HSP90AB1 | |
| SCHEMBL154683 | 0.77 | CHUK (0.61) | CHEK1CHUKMAP3K7TAB1HSP90AB1 | |
| SCHEMBL1737697 | 0.77 | CHEK1 (0.56) | CHEK1CHUKMAP3K7TAB1HSP90AB1 | |
| SCHEMBL5522262 | 0.76 | CHEK1 (0.47) | CHEK1CHUKLRRK2ROCK1 | |
| SCHEMBL311022 | 0.72 | CHEK1 (0.36) | CHEK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169918-B2 | Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-30 | — | — | US | claimed |
| EP-1682564-A1 | METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-26 | — | — | EP | claimed |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. | 2005-09-29 | — | — | US | claimed |
| WO-2005044835-A1 | METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | GENELABS TECHNOLOGIES, INC. (US) | 2005-05-19 | — | — | WO | claimed |
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | PFIZER INC (US) | 2025-05-01 | — | — | US | disclosed |
| US-12077533-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | PFIZER INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20230009153-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-11111242-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | PFIZER INC. (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3318565-B1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3318565-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | Pfizer Inc (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-3077395-B1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170247372-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. (US) | 2017-08-31 | — | — | US | disclosed |
| WO-2008095993-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| US-7169918-B2 | Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169918-B2 | Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7157434-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1682564-A1 | METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005044835-A1 | METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | GENELABS TECHNOLOGIES, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20040147464-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147464-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | CHEK1 1915/4885CHUK 1101/4885MAP3K7 3108/4885 |
| US-12077533-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | ACR, PKD2, PGA5 | CHEK1 718/4885CHUK 1268/4885MAP3K7 1062/4885 |
| US-20170247372-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | JAK2, JAK3, JAK1 | CHEK1 320/4885CHUK 206/4885MAP3K7 29/4885 |
| US-11111242-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | JAK2, JAK3, JAK1 | CHEK1 699/4885CHUK 173/4885MAP3K7 102/4885 |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | HAVCR2, NR4A3, NR2C2 | CHEK1 4549/4885CHUK 2910/4885MAP3K7 3972/4885 |
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | JAK2, JAK3, JAK1 | CHEK1 339/4885CHUK 271/4885MAP3K7 31/4885 |
| US-20230009153-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | JAK2, JAK3, JAK1 | CHEK1 320/4885CHUK 206/4885MAP3K7 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.